Sichuan Good Doctor Panxi Pharmaceutical Co. Ltd. has identified polypeptides reported to be useful for the treatment of inflammatory bowel disease, ulcerative colitis, and dysbacteriosis.
Biogen Inc. has synthesized 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis (MS).
Origenis GmbH has described cyclin-dependent kinase 9 (CDK9) inhibitors, particularly CDK9/cyclin T1, reported to be useful for the treatment of cancer, viral infections, obesity and more.
Almac Discovery Ltd. has described heterocyclic compounds acting as ubiquitin C-terminal hydrolase 7 (USP7; HAUSP) inhibitors reported to be useful for the treatment of cancer.
Betta Pharmaceuticals Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety via a linker reported to be useful for the treatment of cancer.
Researchers from Antengene Biologics Ltd. and Shanghai Antengene Corp. Ltd. have identified ATR kinase inhibitors reported to be useful for the treatment of cancer.
Jazz Pharmaceuticals plc has synthesized novel amine-substituted phthalazines and derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Shanghai Yidian Pharmaceutical Technology Development Co. Ltd. has disclosed peptidyl nitrile compounds acting as cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of cancer, infections, diabetes, respiratory, metabolic, cardiovascular, cerebrovascular and autoimmune disease, among others.
RSS